

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

**VOLUNTARY ANNOUNCEMENT
WAIVER FROM COMPLIANCE WITH SHARE BUY-BACKS CODE**

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) on a voluntary basis to provide shareholders and potential investors of the Company with updated information on the proposal for the repurchase and cancellation of H shares in relation to the 2022 H Share Incentive Scheme as disclosed in the announcement of the Company dated May 23, 2025 and the circular of the Company dated May 28, 2025 (the “**Circular**”). Capitalized terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

The repurchase of the Acquired Award Shares constitutes an off-market share buy-back by the Company under the Share Buy-backs Code. The Company has made an application to the Executive for a waiver from compliance with the requirements of the Share Buy-backs Code (other than Rule 6) pursuant to Rule 8 thereof in respect of the repurchase of the Acquired Award Shares from the Trustee, and the Executive granted such waiver on May 30, 2025.

The repurchase of the Acquired Award Shares is subject to the approval of the shareholders of the Company by way of a special resolution at the forthcoming annual general meeting of the Company to be held on June 19, 2025. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive director

Shanghai, the PRC, June 2, 2025

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.